{"id":"other-art-regimens","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":{"chemblId":"CHEMBL4754894","moleculeType":"Unknown","molecularWeight":"377.52"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"ART regimens typically combine multiple antiretroviral drugs from different classes (nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, entry inhibitors) to suppress HIV replication through complementary mechanisms. Alternative regimens are deployed in treatment-experienced patients, those with drug resistance, or those with contraindications to standard therapies.","oneSentence":"Other ART regimens refer to alternative antiretroviral therapy combinations used to treat HIV infection when standard first-line regimens are not suitable or have failed.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:50:47.925Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-experienced patients"},{"name":"HIV-1 infection with antiretroviral resistance"},{"name":"HIV-1 infection in patients with contraindications to standard first-line regimens"}]},"trialDetails":[{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT03825523","phase":"NA","title":"Immediate ART in Subjects With Opportunistic Diseases","status":"COMPLETED","sponsor":"Gustavo Reyes-Teran","startDate":"2019-02-18","conditions":"HIV/AIDS, ANTIRETROVIRAL TREATMENT","enrollment":114},{"nctId":"NCT03483584","phase":"","title":"Incidence of HANA Conditions in HIV-infected Individuals","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2018-04-06","conditions":"HIV, Metabolic Syndrome, Osteopenia","enrollment":215},{"nctId":"NCT07030920","phase":"PHASE2","title":"Reducing Systemic Inflammation in People on Antiretroviral Therapy","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2025-09-30","conditions":"Human Immunodeficiency Virus (HIV), Cardiovascular Risk Factor","enrollment":150},{"nctId":"NCT06962319","phase":"PHASE3","title":"Safety of Antimalarials in the FIRst trimEster","status":"RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2025-09-30","conditions":"Malaria, Pregnancy, Malaria, Antepartum, Malaria (Uncomplicated)","enrollment":1510},{"nctId":"NCT02859558","phase":"PHASE2","title":"Early ART to Limit Infection and Establishment of Reservoir","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2017-01-24","conditions":"HIV-1 Infection","enrollment":195},{"nctId":"NCT02284035","phase":"PHASE3","title":"Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2015-09-27","conditions":"AIDS","enrollment":75},{"nctId":"NCT05630885","phase":"PHASE2","title":"A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-05-30","conditions":"HIV-1-infection, Elevated Cardiovascular Risk","enrollment":110},{"nctId":"NCT05361148","phase":"","title":"Long-term Health After Severe Acute Malnutrition in Children and Adults: the Role of the Pancreas","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2021-01-12","conditions":"Pancreas Atrophy, Diabetes, Malnutrition","enrollment":2305},{"nctId":"NCT05349838","phase":"PHASE3","title":"Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N","status":"COMPLETED","sponsor":"NEAT ID Foundation","startDate":"2018-11-05","conditions":"HIV-1-infection","enrollment":140},{"nctId":"NCT01380080","phase":"PHASE4","title":"REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-10","conditions":"HIV Infection","enrollment":851},{"nctId":"NCT04032522","phase":"","title":"Neonatal HIV Early Infant Diagnosis (EID) Versus Standard of Care EID- Long Term Impact on inFant hEalth (LIFE)","status":"COMPLETED","sponsor":"Michael Hoelscher","startDate":"2019-10-23","conditions":"HIV, Neonatal HIV Early-Infant-Diagnosis (EID), Point-of-Care Testing (PoC)","enrollment":6602},{"nctId":"NCT02750566","phase":"NA","title":"Comparing the Effect of Osteopathic Manipulative Medicine (OMM) Versus Counseling in the Treatment of Concussion","status":"COMPLETED","sponsor":"New York Institute of Technology","startDate":"2015-11-15","conditions":"Post-Concussion Symptoms, Distorted; Balance","enrollment":33},{"nctId":"NCT05979714","phase":"NA","title":"The Cheeky Study: A Novel Delivery System for CAB-RPV LA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Public Health Foundation Enterprises, Inc.","startDate":"2023-05-31","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT02120352","phase":"PHASE2","title":"A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-04-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":309},{"nctId":"NCT05824130","phase":"","title":"Clinical Outcomes in HIV With Comorbidities","status":"UNKNOWN","sponsor":"Grace Lui","startDate":"2023-04-13","conditions":"Hiv","enrollment":300},{"nctId":"NCT00955968","phase":"PHASE4","title":"IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-01-01","conditions":"HIV Infection","enrollment":1653},{"nctId":"NCT02712801","phase":"PHASE4","title":"Antiretroviral Regime for Viral Eradication in Newborns","status":"COMPLETED","sponsor":"National Center for Women and Children's Health, China CDC","startDate":"2016-04","conditions":"HIV/AIDS and Infections","enrollment":600},{"nctId":"NCT05415891","phase":"NA","title":"The IMPROV Project: Improving Mental Health and Substance Use Treatment Provision (IMPROV) Among People Living With HIV (Human Immunodeficiency Virus) in Atlanta","status":"UNKNOWN","sponsor":"RTI International","startDate":"2022-06","conditions":"Mental Health Disorder, Substance Use Disorder, Stigmatization","enrollment":333},{"nctId":"NCT03251144","phase":"PHASE1, PHASE2","title":"Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2019-04-01","conditions":"HIV/AIDS, Antiviral Toxicity, Antiviral Drug Adverse Reaction","enrollment":26},{"nctId":"NCT00006604","phase":"PHASE1, PHASE2","title":"Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-11","conditions":"HIV Infections","enrollment":195},{"nctId":"NCT03602690","phase":"PHASE2","title":"Evaluation of Third-line cART Regimen in Cambodia (3DICAM)","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2018-10-04","conditions":"HIV/AIDS","enrollment":54},{"nctId":"NCT02707861","phase":"PHASE3","title":"Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1","status":"COMPLETED","sponsor":"TaiMed Biologics Inc.","startDate":"2016-03","conditions":"HIV","enrollment":79},{"nctId":"NCT00735072","phase":"PHASE4","title":"Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-09","conditions":"HIV Infection","enrollment":45},{"nctId":"NCT02431975","phase":"PHASE4","title":"Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial","status":"COMPLETED","sponsor":"Columbia University","startDate":"2015-08","conditions":"HIV","enrollment":73},{"nctId":"NCT01225406","phase":"","title":"Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2010-08","conditions":"This Study is Designed to Collect Treatment Data of Thai Children on Third Line ARV Therapy","enrollment":56},{"nctId":"NCT02995824","phase":"","title":"Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2002-01","conditions":"Liver Transplantation, HIV Infections, Antiretroviral Therapy","enrollment":271},{"nctId":"NCT01078233","phase":"","title":"Observational Data Analysis in EuroSIDA (MK-0518-058)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-05-05","conditions":"HIV-1 Infections","enrollment":6617},{"nctId":"NCT03646370","phase":"","title":"Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2018-07-25","conditions":"HIV-1-infection, Metabolic Syndrome, Cardiovascular Diseases","enrollment":110},{"nctId":"NCT01641367","phase":"PHASE4","title":"A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-02-22","conditions":"HIV-1 Infection","enrollment":545},{"nctId":"NCT01845701","phase":"PHASE3","title":"Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon","status":"COMPLETED","sponsor":"University of Yaounde 1","startDate":"2010-03","conditions":"Malaria","enrollment":720},{"nctId":"NCT02500446","phase":"PHASE4","title":"Dolutegravir Impact on Residual Replication","status":"COMPLETED","sponsor":"University of Melbourne","startDate":"2015-09-28","conditions":"HIV","enrollment":40},{"nctId":"NCT02154360","phase":"PHASE1","title":"Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2014-05","conditions":"HIV Infection","enrollment":12},{"nctId":"NCT00751530","phase":"","title":"BRAVO: Background Regimen of Raltegravir on Virologic Outcome","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2008-03-01","conditions":"HIV Infections","enrollment":442},{"nctId":"NCT00491556","phase":"NA","title":"Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2007-10","conditions":"HIV Infections","enrollment":102},{"nctId":"NCT02974348","phase":"PHASE3","title":"Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa","status":"COMPLETED","sponsor":"University of Bamenda","startDate":"2013-01","conditions":"Drug Resistant Malaria Due to Plasmodium Falciparum","enrollment":300},{"nctId":"NCT00852423","phase":"PHASE3","title":"Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2010-06","conditions":"Malaria in Pregnancy","enrollment":3428},{"nctId":"NCT02028676","phase":"PHASE4","title":"Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa","status":"COMPLETED","sponsor":"Medical Research Council","startDate":"2007-03","conditions":"Human Immunodeficiency Virus","enrollment":1206},{"nctId":"NCT01615601","phase":"","title":"An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Janssen Inc.","startDate":"2011-10","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":77},{"nctId":"NCT01939886","phase":"PHASE3","title":"Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2013-04","conditions":"Malaria","enrollment":219},{"nctId":"NCT01044810","phase":"","title":"Effectiveness of Efavirenz-based Regimen in HIV-1-infected Patients With Nevirapine Hypersensitivity","status":"COMPLETED","sponsor":"Bamrasnaradura Infectious Diseases Institute","startDate":"2010-01","conditions":"Treatment Failure, HIV or AIDS, CD4 Cell Counts","enrollment":559},{"nctId":"NCT00647946","phase":"PHASE2","title":"Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2003-02","conditions":"Lipodystrophy","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Other ART regimens","genericName":"Other ART regimens","companyName":"Juan A. Arnaiz","companyId":"juan-a-arnaiz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Other ART regimens refer to alternative antiretroviral therapy combinations used to treat HIV infection when standard first-line regimens are not suitable or have failed. Used for HIV-1 infection in treatment-experienced patients, HIV-1 infection with antiretroviral resistance, HIV-1 infection in patients with contraindications to standard first-line regimens.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}